Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 2, open-label, multicenter study titled ...

Ianalumab added to eltrombopag significantly prolonged the time to treatment failure (TTF) in adults with primary immune thrombocytopenia (ITP), a B cell-driven autoimmune disease, according to phase ...

Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 ...

Novartis’ ianalumab has shown success in the third trial readout in two days, after it met both its endpoints in a Phase III ...

Ianalumab prolonged the duration of safe platelet levels during and after treatment in patients with primary immune thrombocytopenia (ITP) previously treated with corticosteroids1,2 Patients treated ...

An expert discusses the importance of patient education and personalized, flexible treatment planning in managing chronic ...

An expert discusses treatment strategies for immune thrombocytopenic purpura (ITP), emphasizing individualized decisions ...

Here's everything to know about Mandy Moore's three kids: Gus, Ozzie and Louise. Moore and Goldsmith welcomed their son, ...

Patients with immune thrombocytopenic purpura (ITP) often show thyroid antigen-specific antibodies. Researchers conducted a retrospective study to assess the causal link between hashimoto’s ...

In this video, Ronak Mistry, DO, discusses the results of a study presented at ASH Annual Meeting that examined the use of the Bruton tyrosine kinase inhibitor rilzabrutinib in patients with ...

Rilzabrutinib was also associated with significant and sustained improvement in physical fatigue (based on the Immune Thrombocytopenic Purpura Patient Assessment Questionnaire [ITP-PAQ] Item 10 ...